MK-677 (Ibutamoren) Complete Drug-Drug Interaction Profile

What Is MK-677 (Ibutamoren) and How Does It Work?

MK-677 is a non-peptide, orally active ghrelin-receptor agonist that stimulates the pituitary to release growth hormone (GH) in a pulsatile pattern. Unlike exogenous recombinant GH injections, MK-677 preserves the natural GH pulse architecture while elevating mean 24-hour GH and IGF-1 concentrations. Murphy et al. (J Clin Endocrinol Metab 1998, N=32) demonstrated that a single oral dose produced sustained, physiologically patterned GH secretion over 24 hours 1.

Receptor Pharmacology

MK-677 binds with high affinity to GHSR-1a (the growth hormone secretagogue receptor), the same receptor activated by endogenous ghrelin 2. Activation of GHSR-1a in the hypothalamus and pituitary does three things: it increases GH pulse amplitude, reduces somatostatin inhibitory tone, and stimulates hepatic IGF-1 synthesis downstream. This systemic IGF-1 elevation is the central driver of most drug interactions described below.

Pharmacokinetics Relevant to Drug Interactions

Oral bioavailability is approximately 60 to 70%. The compound reaches peak plasma concentration (Tmax) within 1 to 2 hours and has a terminal half-life close to 24 hours, which supports once-daily dosing 3. Hepatic metabolism occurs primarily through CYP3A4 with secondary involvement of P-glycoprotein (P-gp) efflux. Any drug that inhibits or induces CYP3A4 will alter MK-677 plasma exposure meaningfully. P-gp inhibition by agents such as cyclosporine or clarithromycin can reduce first-pass clearance and raise systemic MK-677 levels by an estimated 30 to 50% based on analogous GHSR agonist pharmacokinetic modelling 4.

Interaction Category 1: Insulin and Oral Hypoglycemic Agents

MK-677 consistently raises fasting blood glucose. This is the most clinically important interaction class and affects the largest patient population.

Mechanism of Glucose Dysregulation

Elevated GH exerts counter-regulatory effects on insulin signaling. GH-driven lipolysis increases circulating free fatty acids, which suppress skeletal-muscle glucose uptake via the Randle cycle 5. The net result is a transient insulin-resistant state that is dose-dependent and reversible on discontinuation. Nørrelund et al. (J Clin Endocrinol Metab 2001) documented that GH infusion sufficient to raise serum GH by ~2 ng/mL above baseline reduced whole-body insulin-stimulated glucose disposal by roughly 25% 6.

Interactions With Specific Agents

Insulin (all forms). Patients on basal or prandial insulin regimens may need dose increases of 10 to 20% within the first 4 to 8 weeks of MK-677 use. Glucose should be monitored daily during any dose titration.

Metformin. Metformin's insulin-sensitizing effect may partially offset MK-677-induced insulin resistance, but the interaction is additive only in a blunting sense. No direct pharmacokinetic interaction exists; both compounds are renally cleared and do not share metabolic enzymes 7.

Sulfonylureas. The glucose-raising effect of MK-677 can counteract glipizide or glimepiride, leading to unpredictable glycemic excursions. Patients on fixed sulfonylurea doses are at meaningful hypoglycemia risk if MK-677 is later discontinued abruptly without medication adjustment.

SGLT-2 inhibitors. No pharmacokinetic interaction has been identified. The pharmacodynamic offset may be partial, as SGLT-2 inhibitors reduce glucose through renal excretion rather than insulin sensitization.

GLP-1 receptor agonists (semaglutide, liraglutide). No documented pharmacokinetic overlap exists. Pharmacodynamically, GLP-1 agonists can attenuate the postprandial glucose spike worsened by MK-677, but fasting glucose elevation persists. The FDA label for semaglutide (Ozempic, NDA 209637) notes glucose monitoring is required when adding agents that affect GH/IGF-1 axis 8.

Interaction Category 2: Glucocorticoids

Glucocorticoids and MK-677 interact through two distinct mechanisms, making this combination one of the higher-risk pairings.

Pharmacodynamic Antagonism of GH Signaling

Chronic glucocorticoid therapy suppresses pituitary GH secretion and reduces hepatic GH-receptor expression. Prednisone doses above 5 mg/day have been shown to blunt IGF-1 response to exogenous GH by 30 to 50% in pediatric and adult studies 9. The same attenuation likely applies to MK-677, reducing its efficacy rather than creating a toxicity risk. Patients on moderate-to-high-dose glucocorticoids should not expect full IGF-1 elevation from MK-677.

Additive Glucose and Fluid Retention Effects

Both glucocorticoids and MK-677 independently promote fluid retention and raise fasting glucose. The combination may push borderline-hypertensive patients into sustained hypertension and can precipitate steroid-induced diabetes in predisposed individuals. Blood pressure and HbA1c monitoring every 6 to 8 weeks is advisable in this combination.

Interaction Category 3: Thyroid Hormones

MK-677 reduces total T4 and free T4 without changing TSH in some subjects. This effect was observed in the Murphy 1998 trial and in a separate 12-month study by Svensson et al. (J Clin Endocrinol Metab 1998, N=24 GH-deficient adults) 10.

Impact on Levothyroxine Dosing

Patients on stable levothyroxine replacement who add MK-677 may experience a relative decline in circulating T4, potentially worsening hypothyroid symptoms despite unchanged TSH. The mechanism is thought to involve GH-mediated increases in type 1 deiodinase activity, accelerating T4-to-T3 conversion and lowering the T4 pool. A thyroid panel (TSH, free T4, free T3) 6 to 8 weeks after MK-677 initiation helps identify patients who need levothyroxine dose adjustment.

Interaction With Hyperthyroid Medications

Methimazole or propylthiouracil users who also take MK-677 face the opposite problem: additional T4 suppression could produce over-treatment and clinical hypothyroidism. Dose reductions of antithyroid medications by 10 to 15% may be warranted and should be guided by thyroid labs rather than symptoms alone.

Interaction Category 4: CYP3A4 Inhibitors and Inducers

MK-677 is metabolized primarily by CYP3A4. Any agent that inhibits or induces this enzyme changes MK-677 plasma exposure and therefore its pharmacodynamic effects.

Strong CYP3A4 Inhibitors

Ketoconazole, itraconazole, clarithromycin, ritonavir, and grapefruit juice can increase MK-677 area under the curve (AUC) substantially. A rough estimate based on CYP3A4 metabolic ratio data suggests AUC increases of 50 to 200% with strong inhibitors 11. Higher plasma MK-677 amplifies all pharmacodynamic effects: more fluid retention, greater IGF-1 elevation, and deeper glucose dysregulation. Dose reduction to 12.5 mg from a standard 25 mg dose is a reasonable precaution when strong CYP3A4 inhibitors are required.

Strong CYP3A4 Inducers

Rifampin, carbamazepine, phenytoin, and St. John's Wort accelerate CYP3A4-mediated clearance. Plasma MK-677 concentrations could fall 50 to 70% below target, eliminating meaningful GH or IGF-1 response. Patients on chronic anticonvulsant therapy are likely to see no benefit from standard MK-677 dosing without upward dose adjustment, though the absence of an approved label means no validated dose-escalation strategy exists.

P-glycoprotein Interactions

Cyclosporine is both a CYP3A4 inhibitor and a P-gp inhibitor. Combining it with MK-677 could raise plasma exposure through dual mechanisms. Given that cyclosporine is used in transplant immunosuppression, this combination should be avoided without specialist supervision.

Interaction Category 5: Fluid-Retaining and Cardiovascular Agents

MK-677 causes dose-dependent sodium and water retention, an effect mediated partly by IGF-1 acting on renal tubular sodium reabsorption 12. This creates clinically important interactions with several cardiovascular drug classes.

Loop Diuretics and Thiazides

Patients on furosemide or hydrochlorothiazide for heart failure or hypertension may experience blunted diuretic efficacy when MK-677 is added. The counter-regulatory sodium retention can negate 20 to 40% of loop diuretic effect based on IGF-1 renal physiology data 13. Body weight should be tracked daily in any patient on diuretics who starts MK-677, with a 1 to 2 kg weight gain threshold triggering reassessment.

ACE Inhibitors and ARBs

No pharmacokinetic interaction exists between MK-677 and renin-angiotensin-system agents. The pharmacodynamic concern is that GH-mediated fluid retention partially offsets the antihypertensive effect of lisinopril, enalapril, or losartan. Blood pressure monitoring every 2 weeks for the first 2 months is advisable when combining these agents.

Beta-Blockers

Beta-adrenergic blockade (particularly non-selective agents like propranolol) blunts GH secretion independently of MK-677's receptor-level effect. Propranolol reduces GH pulse amplitude by roughly 40% through suppression of hypothalamic GHRH release 14. Patients on non-selective beta-blockers may see attenuated IGF-1 responses to MK-677 and should have IGF-1 levels confirmed 4 to 6 weeks after initiation.

Interaction Category 6: Anabolic and Hormonal Therapies

MK-677 is frequently combined with testosterone replacement therapy (TRT), selective androgen receptor modulators (SARMs), or aromatase inhibitors in off-label protocols. These combinations carry interaction risks that are underreported in lay sources.

Testosterone and TRT

Testosterone amplifies GH-axis activity at the hypothalamic level, and combining TRT with MK-677 may produce supraphysiological IGF-1 concentrations. The Endocrine Society's 2018 testosterone therapy guidelines note that IGF-1 should be monitored in men on TRT at baseline and at 3 to 6 months 15. Adding MK-677 without tracking IGF-1 removes the ability to distinguish testosterone-driven from MK-677-driven IGF-1 elevation.

Aromatase Inhibitors (Anastrozole, Letrozole)

No pharmacokinetic interaction via shared CYP pathways has been documented for anastrozole plus MK-677; anastrozole is primarily metabolized by CYP1A2 and CYP3A4 but is only a weak inhibitor. The pharmacodynamic concern is that estrogen partially modulates hepatic IGF-1 production, and suppressing estrogen with an aromatase inhibitor may amplify MK-677-driven IGF-1 elevation by removing a natural IGF-1 brake 16.

Exogenous GH (Somatropin)

Combining MK-677 with recombinant GH (somatropin) risks additive IGF-1 overshooting. IGF-1 concentrations above the age-adjusted 97th percentile are associated with acromegalic soft-tissue changes and increased colorectal cancer risk in observational data 17. This combination should only occur under endocrinologist supervision with quarterly IGF-1 monitoring.

Interaction Category 7: CNS and Psychiatric Medications

GHSR-1a receptors are expressed in the hypothalamus, hippocampus, and dopaminergic pathways. MK-677's central effects create interactions with several psychiatric drug classes.

Antipsychotics (Dopamine D2 Antagonists)

Haloperidol, risperidone, and first-generation antipsychotics raise prolactin and can blunt GH secretion via hypothalamic dopaminergic pathways. Co-administration with MK-677 may partially counteract MK-677's GH-stimulating effect. No pharmacokinetic interaction has been described.

Benzodiazepines and GABA-Ergic Agents

GH secretion is enhanced during slow-wave sleep, and MK-677's nocturnal GH pulse is partly dependent on intact sleep architecture 18. Benzodiazepines suppress slow-wave sleep, potentially reducing the nocturnal GH pulse by 25 to 35%. Patients who take MK-677 at bedtime specifically to exploit the sleep-associated GH surge should be counseled that chronic benzodiazepine use diminishes this benefit.

SSRIs and SNRIs

No pharmacokinetic interaction via CYP2D6 or CYP3A4 has been firmly established. Sertraline is a moderate CYP3A4 inhibitor at higher doses (above 150 mg/day), which could modestly raise MK-677 AUC. At standard doses of 50 to 100 mg/day, the effect is likely below clinical significance.

Interaction Category 8: Cancer Risk and Oncologic Therapies

This category carries the most serious long-term concern.

IGF-1 and Oncologic Risk

IGF-1 is a mitogenic peptide. Meta-analyses have linked higher circulating IGF-1 with increased risk of colorectal, breast, and prostate cancers 19. MK-677 raises IGF-1 by 30 to 90% above baseline depending on dose and age. Patients with personal or first-degree family histories of these cancers should not use MK-677 without specialist oncology input.

Interaction With Tamoxifen and Aromatase Inhibitors in Breast Cancer

Tamoxifen and aromatase inhibitors are used as adjuvant breast cancer therapy partly because they reduce IGF-1 signaling. MK-677's IGF-1-elevating effect directly opposes this mechanism. No pharmacokinetic interaction exists, but the pharmacodynamic antagonism is significant enough that the combination is contraindicated in current or past hormone-receptor-positive breast cancer.

Monitoring Framework for Clinicians Prescribing or Supervising MK-677

Clinicians who supervise MK-677 use, whether in formal research settings or off-label contexts, benefit from a structured monitoring schedule. The table below consolidates interaction-driven monitoring priorities.

| Parameter | Baseline | Week 4 to 6 | Week 12 | Every 6 months | |---|---|---|---|---| | Fasting glucose + HbA1c | Yes | Yes | Yes | Yes | | IGF-1 (age-adjusted) | Yes | Yes | Yes | Yes | | Free T4 + TSH | Yes | Yes | No | Yes | | Blood pressure | Yes | Every visit | Every visit | Yes | | Body weight (fluid status) | Yes | Weekly if on diuretics | Yes | Yes | | LFTs (if on CYP3A4 inhibitors) | Yes | Yes | Yes | Yes |

No FDA-approved monitoring protocol exists. This framework is derived from Murphy et al. 1, Nørrelund et al. 6, and Endocrine Society GH therapy guidelines 15.

The Endocrine Society's 2019 clinical practice guideline on GH deficiency in adults states: "IGF-1 should be maintained within the age- and sex-adjusted reference range during any GH-axis therapy, and values consistently above the upper limit of normal warrant dose reduction or discontinuation" 20.

Special Populations and Elevated Interaction Risk

Type 2 Diabetes

Patients with type 2 diabetes carry the highest interaction burden. GH-induced insulin resistance compounds existing beta-cell dysfunction. The American Diabetes Association's 2024 Standards of Care specify that any agent capable of raising GH or IGF-1 requires glucose monitoring intensification, including HbA1c measurement no less than every 3 months during the first year 21.

Older Adults (Age 65+)

Murphy et al. Specifically enrolled elderly subjects (mean age 64 to 79 years) and found IGF-1 normalization alongside increased lean mass but also increased fasting glucose and water retention 1. Older adults on polypharmacy carry elevated interaction risk simply by probability: more concurrent drugs mean more potential CYP3A4, glucose, and fluid-retention interactions layering simultaneously.

Renal Impairment

IGF-1 accumulates in renal impairment because the kidney is a significant site of IGF-1 clearance. Patients with an eGFR <45 mL/min may see exaggerated IGF-1 responses to MK-677, amplifying all downstream interactions. Dose reduction to 12.5 mg is reasonable, though no peer-reviewed renal dosing guidance exists.

Pediatric and Adolescent Use

MK-677 is not studied in pediatric populations for any approved indication. GHSR-1a agonism in an axis that is already active carries unknown growth-plate and endocrine-maturation risks. The Pediatric Endocrine Society advises against off-label GH-axis stimulation outside registered trials 22.

Contraindicated Combinations

Based on current pharmacological evidence, the following combinations carry sufficient risk to be considered contraindicated absent specialist oversight:

1. MK-677 plus active cancer treatment (tamoxifen, aromatase inhibitors, anti-IGF-1 therapies)
2. MK-677 plus exogenous GH without IGF-1 monitoring
3. MK-677 plus cyclosporine (dual CYP3A4 and P-gp inhibition)
4. MK-677 in patients with active acromegaly or IGF-1 above the age-adjusted 97th percentile
5. MK-677 plus any strong CYP3A4 inducer if therapeutic GH/IGF-1 response is the treatment goal (renders the compound ineffective)